NZ510931A - Polylactide-polyglycolide (PLGA) sustained release formula containing at least 50% active ingredient - Google Patents

Polylactide-polyglycolide (PLGA) sustained release formula containing at least 50% active ingredient

Info

Publication number
NZ510931A
NZ510931A NZ510931A NZ51093197A NZ510931A NZ 510931 A NZ510931 A NZ 510931A NZ 510931 A NZ510931 A NZ 510931A NZ 51093197 A NZ51093197 A NZ 51093197A NZ 510931 A NZ510931 A NZ 510931A
Authority
NZ
New Zealand
Prior art keywords
plga
polyglycolide
polylactide
active ingredient
sustained release
Prior art date
Application number
NZ510931A
Inventor
Supplied Not
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9614755A external-priority patent/FR2756493B1/en
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of NZ510931A publication Critical patent/NZ510931A/en

Links

Abstract

A solid delayed-release formulation, intended to be placed in a body, containing at least one active principle and a biodegradable excipient, wherein the excipient is a polyactide-glycolide (PLGA) copolymer, the concentration of the active principle is over 40% and the excipient does not form a matrix containing the active principle, whereby the release profile of the active principle is constant and the duration of release is substantially greater in vivo than in physiological aqueous medium in vitro. A process of preparation of this delayed-release formulation is also described.
NZ510931A 1996-12-02 1997-12-02 Polylactide-polyglycolide (PLGA) sustained release formula containing at least 50% active ingredient NZ510931A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614755A FR2756493B1 (en) 1996-12-02 1996-12-02 DEVICE FOR LOCAL ADMINISTRATION OF SOLID OR SEMI-SOLID FORMULATIONS
NZ336074A NZ336074A (en) 1996-12-02 1997-12-02 Solid or semi-solid formulation for placement at a precise deposition site formulated for local effect

Publications (1)

Publication Number Publication Date
NZ510931A true NZ510931A (en) 2002-12-20

Family

ID=26233134

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510931A NZ510931A (en) 1996-12-02 1997-12-02 Polylactide-polyglycolide (PLGA) sustained release formula containing at least 50% active ingredient

Country Status (1)

Country Link
NZ (1) NZ510931A (en)

Similar Documents

Publication Publication Date Title
UA29563C2 (en) Microcapsule for prolonged release of physiologically active peptide
HU9501942D0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
CA2195119A1 (en) Formulations and methods for providing prolonged local anesthesia
MXPA01006926A (en) Formulations for treating disease and methods of using same.
HUT60632A (en) Process for producing pharmaceutical compositions with continuous release of active ingredient
MY113268A (en) Plasticized bioerodible controlled delivery system
IL122663A0 (en) Controlled release formulations for poorly soluble drugs
PT839525E (en) PROLONGED LIBERATION PREPARATION
CA2274485A1 (en) Medicinal composition
ATE198152T1 (en) ORAL MEDICINAL PREPARATION WITH DELAYED RELEASE OF ACTIVE INGREDIENTS
UA66812C2 (en) Drug formulation with controlled release of active ingredient
PT615754E (en) SOLID FORMS OF CONTROLLED LIBERATION ORAL ADMINISTRATION FLUPERTINE
CA2251966A1 (en) Transdermally administered dextromethorphan as antitussive agent
HUT49808A (en) Process for producing retarde pharmaceutical compositions containing aselastine
EP0848948A4 (en) Long-lasting composition for rectal administration
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
MXPA04003506A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
NZ510931A (en) Polylactide-polyglycolide (PLGA) sustained release formula containing at least 50% active ingredient
CA2384301A1 (en) Sustained-release drug formulations for implantation
IL105569A (en) Pharmaceutical compositions containing remacemide for the treatment of parkinson's disease
IT1244489B (en) Controlled release pharmaceutical composition containing a pharmaceutically acceptable salt of buflomedil
ITBO930460A0 (en) PROCEDURE FOR PREPARING PHARMACEUTICAL FORMS WITH CONTROLLED RELEASE OF THE ACTIVE INGREDIENT AND THE PHARMACEUTICAL FORMS SO OBTAINED.
BG49070A1 (en) Medicinal form for paradontoses treatment
ITBO920455A0 (en) PROCEDURE FOR PREPARING PHARMACEUTICAL FORMS WITH CONTROLLED DELAYED RELEASE OF THE ACTIVE INGREDIENT AND THE PHARMACEUTICAL FORMS SO OBTAINED.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D.APPLICA, FR

Free format text: OLD OWNER(S): DELAB

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired